Latest Conference Articles

December 9th 2023, 10:40pm

ASH Annual Meeting and Exposition

Brexucabtagene autoleucel is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features.

December 9th 2023, 10:36pm

ASH Annual Meeting and Exposition

Revumenib, decitabine/cedazuridine, plus venetoclax elicited an objective response rate of 100% with acceptable safety in patients with relapsed/refractory acute myeloid leukemia enrolled in the small phase 1/2 SAVE study.

December 9th 2023, 10:31pm

ASH Annual Meeting and Exposition

The T-cell redirecting bispecific antibody teclistamab-cqyv demonstrated efficacy and a tolerable safety profile in a real-world population of patients with relapsed/refractory multiple myeloma consistent with that of those enrolled in the phase 2 MajesTEC-1 trial.

December 9th 2023, 8:00pm

ASH Annual Meeting and Exposition

A machine learning, artificial intelligence algorithm analyzing diagnostic bone marrow biopsy digital whole-slide images was able to effectively differentiate with 92.3% accuracy between prefibrotic primary myelofibrosis and essential thrombocythemia.

December 9th 2023, 7:39pm

ASH Annual Meeting and Exposition

Treatment with an all-oral regimen of arsenic trioxide, all-trans retinoic acid, and ascorbic acid led to both 3-year overall survival and relapse-free survival rates of 97% in patients with acute promyelocytic leukemia.

December 9th 2023, 12:10am

San Antonio Breast Cancer Symposium

Beyond genomic testing, endocrine therapy response should be used to determine whether patients with hormone receptor–positive, HER2-negative, N0-1 early breast cancer.

December 8th 2023, 11:19pm

San Antonio Breast Cancer Symposium

Neoadjuvant nivolumab and non–anthracycline containing chemotherapy produced promising pathologic complete response rates regardless of whether nivolumab was administered before or during treatment with carboplatin and paclitaxel in patients with stage I to IIB triple-negative breast cancer.

December 8th 2023, 11:15pm

San Antonio Breast Cancer Symposium

Peter Schmid, MD, PhD, discusses updated event-free survival findings from the phase 3 KEYNOTE-522 trial of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab in patients with early-stage triple-negative breast cancer. 

December 8th 2023, 10:35pm

Seema A. Khan, MD, discusses 5-year clinical outcomes from the ECOG-ACRIN E4112 trial, which is evaluating the use of MRI and a 12-gene expression assay to optimize local therapy for patients with ductal carcinoma in situ.

December 8th 2023, 10:18pm

San Antonio Breast Cancer Symposium

Neoadjuvant pembrolizumab combined with chemotherapy followed by adjuvant pembrolizumab compared with placebo plus chemotherapy continued to show a clinically meaningful improvement in event-free survival in patients with high-risk, early-stage triple-negative breast cancer.

December 8th 2023, 9:48pm

San Antonio Breast Cancer Symposium

Zanidatamab in combination with palbociclib and fulvestrant resulted in positive progression-free survival outcomes and exhibited an acceptable safety profile in patients with hormone receptor–positive, HER2-positive metastatic breast cancer.

December 8th 2023, 9:16pm

San Antonio Breast Cancer Symposium

The addition of atezolizumab to neoadjuvant trastuzumab plus pertuzumab (HP) and chemotherapy led to a numerical, but not statistically significant, increase in pathologic complete response vs HP/chemotherapy alone in patients with HER2-positive operable breast cancer.

December 8th 2023, 9:15pm

San Antonio Breast Cancer Symposium

Real-world data support the use of the MammaPrint index as a predictor of neoadjuvant chemosensitivity in patients with hormone receptor–positive, HER2-negative early-stage breast cancer.

December 8th 2023, 7:55pm

San Antonio Breast Cancer Symposium

Clinical, transcriptomic, and genomic differences that may contribute to aggressive tumor biology were observed between Latin-American and non-Hispanic White patients with breast cancer.

December 8th 2023, 7:46pm

San Antonio Breast Cancer Symposium

Adjuvant ado-trastuzumab emtansine continued to improve overall survival and invasive disease-free survival vs trastuzumab after 8.4 years of follow-up in patients with HER2-positive early breast cancer and residual invasive disease following neoadjuvant therapy enrolled in the phase 3 KATHERINE trial.

December 8th 2023, 5:28pm

San Antonio Breast Cancer Symposium

The brain-penetrant oral selective estrogen receptor degrader SIM0270 exhibited a favorable safety profile and early signals of antitumor activity in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer, including those with ESR1 mutations.

December 8th 2023, 5:07pm

San Antonio Breast Cancer Symposium

A continued statistically significant improvement in iDFS was observed for patients with HR-positive, HER2-negative early-stage breast cancer who received ribociclib plus a nonsteroidal AI vs a nonsteroidal AI alone, according to the final iDFS analysis of the phase 3 NATALEE trial.

December 8th 2023, 4:56pm

San Antonio Breast Cancer Symposium

Treatment with elacestrant led to a clinically meaningful improvement in progression-free-survival compared with standard-of-care therapy among patients with estrogen receptor–positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

December 7th 2023, 11:01pm

San Antonio Breast Cancer Symposium

Senthil Damodaran, MD, PhD, discusses the efficacy of futibatinib plus fulvestrant in patients with FGFR1-amplified metastatic hormone receptor–positive, HER2-negative breast cancer according to findings from the phase 2 FOENIX-MBC2 trial.

December 7th 2023, 10:41pm

San Antonio Breast Cancer Symposium

Anastrozole or fulvestrant plus fam-trastuzumab deruxtecan-nxki demonstrated encouraging antitumor activity in patients with chemotherapy-naïve, HER2-low hormone receptor–positive metastatic breast cancer.